WithdrawnPhase 3NCT03502421

Ketamine Sickle Cell Disease

Studying Sickle cell S-C disease

Last synced from ClinicalTrials.gov May 10, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: University of South Florida
Principal Investigator: Enrico Camporesi, MD
University of South Florida
Intervention: Ketamine(drug)
Eligibility: 18 years · All sexes
Timeline: 2018 – 2019

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03502421 on ClinicalTrials.gov

← Back to all trials